Compare INMD & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INMD | CERT |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.0M | 860.9M |
| IPO Year | 2018 | 2020 |
| Metric | INMD | CERT |
|---|---|---|
| Price | $14.02 | $4.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $17.33 | $11.67 |
| AVG Volume (30 Days) | 716.6K | ★ 3.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $1.74 | $4.18 |
| Revenue Next Year | $3.26 | $5.39 |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $12.72 | $4.45 |
| 52 Week High | $16.74 | $13.88 |
| Indicator | INMD | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 29.39 |
| Support Level | $14.00 | N/A |
| Resistance Level | $14.70 | $6.47 |
| Average True Range (ATR) | 0.30 | 0.31 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 59.92 | 11.22 |
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.